Chinese commercial-stage biopharmaceutical company IASO Biotechnology (IASO Bio) announced on Saturday the presentation of first-in-human (FIH) Phase 1 clinical data for IASO206, its internally developed BCMA-targeted in vivo CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (R/R MM) at the 2026 International Myeloma Society (IMS) Annual Meeting.

IASO206 is designed to generate functional BCMA-directed CAR-T cells directly in patients following a single intravenous infusion, eliminating the need for ex vivo cell manufacturing and lymphodepleting chemotherapy.

The investigator-initiated trial (IIT) enrolled patients with R/R MM who had received at least two prior lines of therapy and had relapsed or refractory disease following treatment with proteasome inhibitors, immunomodulatory agents, and/or anti-CD38 antibodies.

Trial data showed that a single intravenous infusion of IASO206 generated functional BCMA CAR-T cells in vivo without lymphodepleting chemotherapy. The study demonstrated a 90% objective response rate and a 90% minimal residual disease (MRD) negativity rate in a population in which 90% of patients had high-risk and 70% had ultra-high-risk cytogenetic features; both rates reached 100% in the high-dose cohort. IASO206 showed encouraging anti-myeloma activity together with an overall manageable safety profile, supporting its continued clinical development and further evaluation of the optimal dose.